Harrow (HROW) shares soared 12.9% in the last trading session to close at $19.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.5% gain over the past four weeks. This pharmaceutical and drug compounding company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of -1150%. Revenues are expected to be $42.78 million, up 27.8% from the year-ago quarter. For Harr ...

| 17 | Investor Presentation | May 2024 • Steroids, NSAIDs, and Anti-inflammatories • an OTC preservative-free lubricant • an Antihistamine, and Antibiotics cyclosporine ophtha emulsion 0.1% "We know steroids effectively treat inflammation in DED. FLAREX is further differentiated from other steroids by increasing MUC1, MUC4, MUC16, and MUC19 gene expression in the conjunctival and corneal epithelial cells. Mucin is a critical component of DED in providing protection and binding the tear film to the ocular s ...

Harrow, Inc. (NASDAQ:HROW) Q1 2024 Earnings Call Transcript May 14, 2024 8:00 AM ET Company Participants Jamie Webb - Director of Communications and IR Mark L. Baum - CEO Andrew Boll - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Chase Knickerbocker - Craig-Hallum Brooks O'Neil - Lake Street Capital Operator Good day, everyone, and welcome to the Harrow, Inc. First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After toda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Harrow, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or other jurisdiction of incorporation or organization) 102 Woodmont Blvd., Suite 610 Nashville, Tennesse ...

Exhibit 99.2 Letter to Stockholders May 13, 2024 Dear Harrow Stockholders: Today marks the beginning of the 20 week of 2024 and the 134 day into the second year of Harrow's current Five-Year Strategic Plan. This year remains focused on three key operational initiatives: (1) building a formidable dry eye disease franchise, including successfully launching VEVYE; (2) continuing to lay the foundation for Harrow's retina franchise with IHEEZO and TRIESENCE; and (3) stabilizing ImprimisRx and our recently acquir ...

ia_64/iStock via Getty Images Shares of ophthalmology-focused specialty pharmaceutical concern Harrow, Inc. (NASDAQ:HROW) are down some 45% since their highs in the spring of 2023. However, they seem likely to rebound as the market starts to look at the potential for Iheezo. Its launch and that of dry eye therapy Vevye suggest that the company's FY24 net revenue outlook of $180 million plus might be very conservative. In addition, the recent insider and beneficial owner buying also merited a deeper dive. Se ...

Financial Data and Key Metrics Changes - The company achieved record revenues in 2023, increasing by 47% compared to 2022, with adjusted EBITDA more than doubling during the same period [21][34] - The cash position strengthened, ending the year with $83 million in cash and cash equivalents, with expectations for continued growth in cash reserves [35] Business Line Data and Key Metrics Changes - The VEVYE launch is performing exceptionally well, with all key performance metrics trending positively, indicating strong market acceptance [4][23] - IHEEZO has seen continued uptake since its launch in May 2023, with recent developments from CMS regarding its average selling price positively impacting its market potential [37][60] Market Data and Key Metrics Changes - The U.S. dry eye market, where VEVYE operates, was approximately 8 million units last year, indicating a substantial opportunity for growth [36] - The retina market, particularly for intravitreal injections, is significant, exceeding 10 million unit opportunities annually, which the company is targeting [44] Company Strategy and Development Direction - The company aims to dominate the U.S. chronic dry eye disease market with VEVYE, leveraging its unique tolerability profile compared to existing products [36][68] - There is a focus on expanding the sales and marketing efforts for IHEEZO and Triesence to accelerate revenue growth, with plans to invest further in these areas [42][51] Management's Comments on Operating Environment and Future Outlook - Management expressed high confidence in achieving revenue guidance of over $180 million for 2024, citing recent positive developments as a significant boost to their outlook [60][76] - The company is optimistic about the future trajectory of IHEEZO following confirmation from CMS regarding separate reimbursement, which is expected to open up a large market [60][78] Other Important Information - The company has added approximately 100 new employees, primarily for the VEVYE launch, indicating a commitment to scaling operations [27] - A recent cyber-attack affected payment processing, but recovery is expected by the second quarter, with normalization anticipated [65] Q&A Session Summary Question: Can you provide a breakdown of the anticipated contribution from your growth drivers for 2024? - Management reiterated confidence in revenue guidance exceeding $180 million but did not provide specific product guidance [40][51] Question: What is the anticipated cadence for top-line growth this year? - The company expects a linear increase in revenue similar to the previous year [72] Question: How will pricing adjustments impact margins in 2024? - Pricing for Triesence has been adjusted to create profit incentives while remaining competitive, with expectations for margins to vary based on revenue growth [54][72]

"VEVYE represents a breakthrough in dry eye treatment. Patients with sensitive eyes, often susceptible to side effects from prescription eyedrops, finally have a solution. VEVYE is the first topical immunomodulator that hasn't had any side effects of stinging, while also having the highest concentration of cyclosporine on the market. Unsurprisingly, the feedback from patients has been tremendous." "VEVYE's performance has been outstanding in terms of accessibility, especially for a new entrant to the pharma ...

Exhibit 99.2 Letter to Stockholders March 19, 2024 Dear Harrow Stockholders: Please review our new corporate presentation to supplement this Letter to Stockholders. Four Years of Accomplishment The legendary investor Warren Buffett once said, "Some people like to get rich quick, but I like to get rich slow." Buffett often quoted his friend and former Goldman Sachs senior executive, Gustave "Gus" Levy, who said, "Short-term greed leads to bad long-term results." And finally, my friend Don Miloni – who helped ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 HARROW, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...